MOUNTAIN VIEW, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on recent developments.
“We are pleased to be underway in our randomized clinical trial of IGM-8444 in combination with standard of care FOLFIRI chemotherapy and bevacizumab in second line metastatic colorectal cancer patients, and we look forward to presenting additional clinical data in the middle of 2023 from our non-randomized Phase 1 clinical study of 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “We are also looking forward to the start of clinical testing of imvotamab in autoimmune diseases, where we believe the clinical safety and efficacy profile of imvotamab positions us very well for the exciting new area of treating autoimmune disease with T cell engagers.”
Pipeline Updates
IGM-8444 (DR5)
Imvotamab (CD20 x CD3)
IGM-7354 (IL-15 x PD-L1)
IGM-2644 (CD38 x CD3)
First Quarter 2023 Financial Results
2023 Financial Guidance
The Company expects full year 2023 GAAP operating expenses of $275 million to $285 million, including estimated non-cash stock-based compensation expense of approximately $45 million, and full year collaboration revenue of approximately $3 million related to the Sanofi agreement. The Company expects to end 2023 with a balance of more than $200 million in cash and investments, and for the balance to enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024.
About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases and infectious diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements relating to the Company’s plans, expectations and forecasts and to future events. Such forward-looking statements include, but are not limited to: the potential of, and expectations regarding, the Company’s technology platform and its IgM antibodies and product candidates, including IGM-8444, imvotamab, IGM-7354 and IGM-2644; the Company’s plans and expectations regarding its clinical development efforts and activities; statements regarding the clinical development of IGM-8444, imvotamab, IGM-7354 and IGM-2644, including the timing of initiation of clinical trials, patient enrollment and release of clinical data; the Company’s expectations regarding its financial position and guidance, including collaboration revenue, operating expenses, stock-based compensation expense, ending 2023 cash and investments and projected cash runway; and statements by the Company’s Chief Executive Officer. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including but not limited to: the Company’s early stages of clinical drug development; risks related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; the Company’s ability to demonstrate the safety and efficacy of its product candidates; the Company’s ability to successfully and timely advance its product candidates through preclinical studies and clinical trials; the Company’s ability to enroll patients in its clinical trials; the potential for the results of clinical trials to differ from preclinical, preliminary, initial or expected results; the risk of significant adverse events, toxicities or other undesirable side effects; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of collaborations with third parties; the Company’s ability to successfully manufacture and supply its product candidates for clinical trials; the potential impact of continuing or worsening supply chain constraints; the risk that all necessary regulatory approvals cannot be obtained; the potential market for the Company’s product candidates, and the progress and success of alternative therapeutics currently available or in development; the Company’s ability to obtain additional capital to finance its operations, if needed; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company’s ability to obtain, maintain and protect its intellectual property rights; developments relating to the Company’s competitors and its industry, including competing product candidates and therapies; any potential delays or disruptions resulting from catastrophic events, including epidemics or other outbreaks of infectious disease; general economic and market conditions, including inflation; and other risks and uncertainties, including those more fully described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 12, 2023 and in the Company’s future reports to be filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, except as required by law.
Contact:
Argot Partners
David Pitts
212-600-1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
| IGM Biosciences, Inc. | ||||||||
| Selected Statement of Operations Data | ||||||||
| (unaudited) | ||||||||
| (in thousands, except share and per share data) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2023 | 2022 | |||||||
| Collaboration revenue | $ | 522 | $ | — | ||||
| Operating expenses: | ||||||||
| Research and development (1) | 50,894 | 38,875 | ||||||
| General and administrative (1) | 13,002 | 13,081 | ||||||
| Total operating expenses | 63,896 | 51,956 | ||||||
| Loss from operations | (63,374 | ) | (51,956 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 4,172 | 54 | ||||||
| Other income (expense) | (20 | ) | 8 | |||||
| Total other income (expense) | 4,152 | 62 | ||||||
| Loss before income tax expense | (59,222 | ) | (51,894 | ) | ||||
| Income tax expense | (87 | ) | — | |||||
| Net loss | $ | (59,309 | ) | $ | (51,894 | ) | ||
| Net loss per share, basic and diluted | $ | (1.33 | ) | $ | (1.53 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 44,466,764 | 33,838,895 | ||||||
| (1) Amounts include stock-based compensation expense as follows: | ||||||||
| Research and development | $ | 6,439 | $ | 6,607 | ||||
| General and administrative | 4,608 | 4,892 | ||||||
| Total stock-based compensation expense | $ | 11,047 | $ | 11,499 | ||||
| IGM Biosciences, Inc. | ||||||||
| Selected Balance Sheet Data | ||||||||
| (unaudited) | ||||||||
| (in thousands) | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Cash and investments | $ | 373,396 | $ | 427,162 | ||||
| Total assets | 462,742 | 513,499 | ||||||
| Accounts payable | 3,972 | 2,512 | ||||||
| Accrued liabilities | 29,637 | 33,621 | ||||||
| Deferred revenue | 148,409 | 148,931 | ||||||
| Total liabilities | 223,312 | 226,236 | ||||||
| Accumulated deficit | (634,135 | ) | (574,826 | ) | ||||
| Total stockholders' equity | 239,430 | 287,263 | ||||||
| Last Trade: | US$1.72 |
| Daily Change: | 0.02 1.18 |
| Daily Volume: | 445,584 |
| Market Cap: | US$58.620M |
November 08, 2024 November 04, 2024 September 10, 2024 August 14, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
